Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Protalix Biotherapeutics Inc    PLX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
11/13/2017 11/14/2017 11/15/2017 11/16/2017 11/17/2017 Date
0.72(c) 0.6811(c) 0.6729(c) 0.66(c) 0.67(c) Last
952 103 1 052 128 489 899 696 197 596 124 Volume
+3.78% -5.40% -1.20% -1.92% +1.52% Change
More quotes
Financials ($)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
P/E ratio 2013 -
P/E ratio 2014
Capi. / Sales2013 5,94x
Capi. / Sales2014 2,62x
Capitalization 93,6 M
More Financials
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system.It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.The... 
More about the company
Surperformance© ratings of Protalix Biotherapeutics I
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTALIX BIOTHERAPEUTICS I
11/15 PROTALIX BIOTHERAPEUTICS : Receives Positive Opinion for Orphan Designation for ..
11/14 PROTALIX BIOTHERAPEUTICS : Receives Positive Opinion for Orphan Designation for ..
11/13 PROTALIX BIOTHERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits..
11/13 Protalix BioTherapeutics Receives Positive Opinion for Orphan Designation for..
11/08 PROTALIX BIOTHERAPEUTICS : Management's Discussion and Analysis of Financial Con..
11/08 PROTALIX BIOTHERAPEUTICS : reports 3Q loss
11/08 PROTALIX BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition (..
11/08 Protalix BioTherapeutics Reports 2017 Third Quarter Results and Provides Corp..
11/02 PROTALIX BIOTHERAPEUTICS : to Hold Third Quarter 2017 Financial Results and Corp..
10/31 Protalix BioTherapeutics to Hold Third Quarter 2017 Financial Results and Cor..
More news
Sector news : Biotechnology & Medical Research - NEC
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
More sector news : Biotechnology & Medical Research - NEC
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix Biotherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 6,50 $
Spread / Average Target 848%
EPS Revisions
Managers
NameTitle
Moshe Manor President, Chief Executive Officer & Director
Shlomo Yanai Chairman
Tzvi Palash Chief Operating Officer
Yossi Maimon CFO, Secretary, Treasurer & Vice President
Yoseph Shaaltiel Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PROTALIX BIOTHERAPEUTICS INC53.06%94
CELLTRION, INC.--.--%24 558
INCYTE CORPORATION5.19%22 258
IQVIA HOLDINGS INC37.36%22 074
LONZA GROUP59.52%19 560
ALNYLAM PHARMACEUTICALS, INC.240.57%12 538